Details of Host Protein-DME Interaction (HOSPPI)
| General Information of Drug-Metabolizing Enzyme (DME ID: DME0523) | |||||
|---|---|---|---|---|---|
| DME Name | Glucose-6-phosphatase beta (G6PC3), Homo sapiens | DME Info | |||
| UniProt ID | |||||
| EC Number | EC: 3.1.3.9 (Click to Show/Hide the Complete EC Tree) | ||||
| Lineage | Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) | ||||
| Interactome | |||||
| Disease Specific Interactions between Host Protein and DME (HOSPPI) | |||||
|---|---|---|---|---|---|
| ICD Disease Classification 02 Neoplasms | |||||
| ICD-11: 2A00 Brain cancer | Click to Show/Hide the Full List of HOSPPI: 2 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Brain neuroepithelial tumour | Moderate hypomethylation | |||
| Interaction Name | DNMT-G6PC3 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 3.97E-13; delta-beta: -2.23E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the G6PC3 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Glucose-6-phosphatase beta. As a result, the interaction between DNMT and G6PC3 can moderatly affect the drug-metabolizing process of Glucose-6-phosphatase beta. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Myxopapillary ependymoma | Moderate hypomethylation | |||
| Interaction Name | DNMT-G6PC3 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 2.73E-09; delta-beta: -2.05E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the G6PC3 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Glucose-6-phosphatase beta. As a result, the interaction between DNMT and G6PC3 can moderatly affect the drug-metabolizing process of Glucose-6-phosphatase beta. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C12 Liver cancer | Click to Show/Hide the Full List of HOSPPI: 2 HOSPPI | ||||
| Non-coding RNA regulation | |||||
| hsa-miR-122-5p | Liver cancer | Suppression | |||
| miRBase ID | |||||
| Interaction Name | hsa-miR-122-5p--G6PC3 regulation | [2] | |||
| Studied Cell Lines | Mahlavu and SK-HEP-1 cell lines | ||||
| Description | hsa-miR-122-5p is reported to suppress G6PC3 mRNA translation by binding to the 3' untranslated region (3'UTR) of G6PC3 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Glucose-6-phosphatase beta. | ||||
| Histone modification | |||||
| Histone deacetylase 4 (HDAC4) | Liver cancer | Repression | |||
| Uniprot ID | |||||
| Interaction Name | HDAC4-G6PC3 interaction | [1] | |||
| Studied Cell Lines | HepG2 cell line | ||||
| Description | Histone deacetylase 4 (HDAC4) is reported to deacetylate the G6PC3 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Glucose-6-phosphatase beta. As a result, the interaction between HDAC4 and G6PC3 can inhibit the drug-metabolizing process of Glucose-6-phosphatase beta. | ||||
| ICD-11: 2C82 Prostate cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Prostate cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-G6PC3 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 1.36E-04; delta-beta: 4.08E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the G6PC3 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Glucose-6-phosphatase beta. As a result, the interaction between DNMT and G6PC3 can significantly affect the drug-metabolizing process of Glucose-6-phosphatase beta. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2E06 Prostate cancer metastasis | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Prostate cancer metastasis | Moderate hypermethylation | |||
| Interaction Name | DNMT-G6PC3 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 9.08E-04; delta-beta: 2.01E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the G6PC3 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Glucose-6-phosphatase beta. As a result, the interaction between DNMT and G6PC3 can moderatly affect the drug-metabolizing process of Glucose-6-phosphatase beta. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.